These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25673314)

  • 1. Raynaud's Syndrome: a neglected disease.
    Poredos P; Poredos P
    Int Angiol; 2016 Apr; 35(2):117-21. PubMed ID: 25673314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evidence-based therapy of Raynaud's syndrome].
    Distler M; Distler J; Ciurea A; Kyburz D; Müller-Ladner U; Reich K; Distler O
    Z Rheumatol; 2006 Jul; 65(4):285-9. PubMed ID: 16804699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
    Linnemann B; Erbe M
    Vasa; 2016; 45(3):201-12. PubMed ID: 27129065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Raynaud's syndrome, 2011].
    Takáts A; Garai I; Papp G; Hevér T; Csiki E; András C; Csiki Z
    Orv Hetil; 2012 Mar; 153(11):403-9. PubMed ID: 22390864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the treatment of Raynaud's phenomenon.
    Levien TL
    Vasc Health Risk Manag; 2010 Mar; 6():167-77. PubMed ID: 20448801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raynaud's phenomenon: Current concepts.
    Stringer T; Femia AN
    Clin Dermatol; 2018; 36(4):498-507. PubMed ID: 30047433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iloprost treatment in pediatric patients with complicated Raynaud's phenomenon.
    Cekic S; Kilic SS
    Lupus; 2016 Apr; 25(5):558-60. PubMed ID: 26692039
    [No Abstract]   [Full Text] [Related]  

  • 9. Raynaud's Phenomenon.
    Wigley FM; Flavahan NA
    N Engl J Med; 2016 Aug; 375(6):556-65. PubMed ID: 27509103
    [No Abstract]   [Full Text] [Related]  

  • 10. Is iloprost effective in secondary Raynaud's phenomenon?
    Lustig N; Rada G
    Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnosis and treatment of Raynaud's phenomenon: a practical approach.
    Pope JE
    Drugs; 2007; 67(4):517-25. PubMed ID: 17352512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joint hypermobility syndrome and bilateral total occlusion of the ulnar arteries presenting as Raynaud's phenomenon.
    Haberhauer G; Feyertag J; Hanusch-Enserer U; Dunky A
    Clin Exp Rheumatol; 2000; 18(2):270-1. PubMed ID: 10812513
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geriatrics photo quiz. Raynaud's: classic "blue fingertips'.
    Gross JS; Shua-Haim JR
    Geriatrics; 1996 May; 51(5):10, 21. PubMed ID: 8621099
    [No Abstract]   [Full Text] [Related]  

  • 15. Raynaud's phenomenon.
    O'connor CM
    J Vasc Nurs; 2001 Sep; 19(3):87-92; quiz 93-4. PubMed ID: 11533581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Raynaud's phenomenon.
    García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Pardo-Santos R; Levy R; Maldonado CG; Chávez GP; Cervera R
    Autoimmun Rev; 2008 Oct; 8(1):62-8. PubMed ID: 18692160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How I treat...Raynaud's phenomenon].
    Piérard GE
    Rev Med Liege; 1998 Mar; 53(3):119-20. PubMed ID: 9594609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of Raynaud's phenomenon].
    Lazareth I
    Ann Dermatol Venereol; 2001 Apr; 128(4):553-6. PubMed ID: 11395659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.